Mechanistic Insights for Optimizing PSMA Radioligand Therapy | Citedby Results | Clinical Cancer Research | American Association for Cancer Research

Skip to Main Content

Skip Nav Destination

Mechanistic Insights for Optimizing PSMA Radioligand Therapy

Clin Cancer Res (2020) 26 (12): 2774–2776.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMA and Beyond

Andrei Gafita
Charles Marcus
Louise Kostos
David M. Schuster
Jeremie Calais
Michael S. Hofman

American Society of Clinical Oncology Educational Book (2022) (42): 366.

DOTA Conjugate of Bisphosphonate and PSMA-Inhibitor: A Promising Combination for Therapy of Prostate Cancer Related Bone Metastases

Tilmann Grus
Hanane Lahnif
Nicole Bausbacher
Matthias Miederer
Frank Rösch

Frontiers in Nuclear Medicine (2022) 2

Pretherapeutic estimated glomerular filtration rate predicts development of chronic kidney disease in patients receiving PSMA‐targeted radioligand therapy

Liam Widjaja
Thorsten Derlin
Tobias L. Ross
Frank M. Bengel
Rudolf A. Werner

The Prostate (2022) 82 (1): 86.

First Experiences with 177Lu-PSMA Therapy in Combination with Pembrolizumab or After Pretreatment with Olaparib in Single Patients

Vikas Prasad
Friedemann Zengerling
Jochen P. Steinacker
Christian Bolenz
Meinrad Beer
Thomas Wiegel
Matthias Eiber
Neil Fleshner
Ambros J. Beer

Journal of Nuclear Medicine (2021) 62 (7): 975.

Immune Checkpoints, Inhibitors and Radionuclides in Prostate Cancer: Promising Combinatorial Therapy Approach

Mankgopo M. Kgatle
Tebatso M. G. Boshomane
Ismaheel O. Lawal
Kgomotso M. G. Mokoala
Neo P. Mokgoro
Nico Lourens
Kalevo Kairemo
Jan Rijn Zeevaart
Mariza Vorster
Mike M. Sathekge

International Journal of Molecular Sciences (2021) 22 (8): 4109.

Target Heterogeneity in Oncology: The Best Predictor for Differential Response to Radioligand Therapy in Neuroendocrine Tumors and Prostate Cancer

Ameya D Puranik
Clarisse Dromain
Neil Fleshner
Mike Sathekge
Marianne Pavel
Nina Eberhardt
Friedemann Zengerling
Ralf Marienfeld
Michael Grunert
Vikas Prasad

Cancers (2021) 13 (14): 3607.

Radionuclide Therapy in Prostate Cancer: From Standalone to Combination PSMA Theranostics

Shahneen Sandhu
Christina Guo
Michael S. Hofman

Journal of Nuclear Medicine (2021) 62 (12): 1660.

Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting

Andrea K. Miyahira
Kenneth J. Pienta
John W. Babich
Neil H. Bander
Jeremie Calais
Peter Choyke
Michael S. Hofman
Steven M. Larson
Frank I. Lin
Michael J. Morris
Martin G. Pomper
Shahneen Sandhu
Howard I. Scher
Scott T. Tagawa
Scott Williams
Howard R. Soule

The Prostate (2020) 80 (15): 1273.